CDK2基因沉默联合达卡巴嗪对B16?F1黑素瘤的生长抑制作用

摘要/Abstract

摘要： 目的探讨CDK2基因沉默后对达卡巴嗪（DTIC）治疗B16?F1黑素瘤抑瘤效应的影响。方法实验设对照组、CDK2?shRNA组、DTIC组、CDK2?shRNA + DTIC组，MTT法检测各组细胞生长抑制情况，计算药物相互作用指数（CDI值），AnnexinV?FITC/ PI双染法检测细胞凋亡情况。建立C57 BL/6小鼠B16?F1细胞移植瘤模型，分组实验，持续观察18 d，绘制肿瘤生长曲线，计算肿瘤生长抑制率，TUNEL检测肿瘤组织细胞凋亡情况。结果与对照组相比，CDK2?shRNA组、DTIC组、CDK2?shRNA + DTIC组在72h的细胞相对存活率分别为（40.6 ± 2.8）%、（45.2 ± 3.7）%、（28.7 ± 2.1）%，细胞凋亡率分别为（25.1 ± 3.3）%、（15.6 ± 2.2）%和（45.6 ± 3.5）%，细胞相对存活率显著降低（F = 458.04，P < 0.05）而细胞凋亡率显著升高（F = 115.46，P < 0.05），其中CDK2?shRNA + DTIC组比DTIC组的细胞相对存活率显著降低（P < 0.01），而细胞凋亡率显著升高（P < 0.01）；两药相互作用指数（CDI值） < 0.7。治疗第6天，对照组、CDK2?shRNA组、DTIC组及CDK2?shRNA + DTIC组的肿瘤体积分别为（185.44 ± 68.97） mm3、（83.91 ± 14.33） mm3、（123.70 ± 20.85） mm3、（34.54 ± 10.72） mm3。从治疗的第6天开始，与对照组相比，CDK2?shRNA组、DTIC组及CDK2?shRNA + DTIC组的肿瘤生长速度明显降低（F = 11.819，P < 0.05），而CDK2?shRNA + DTIC组的肿瘤生长速度明显低于DTIC组（P = 0.04）；与对照组相比，CDK2?shRNA组、DTIC组、CDK2?shRNA + DTIC组的肿瘤生长抑制率分别为52.2%、41.2%、86.4%，组织细胞凋亡指数分别为（32.93 ± 3.72）%、（21.62 ± 3.54）%、（63.29 ± 4.74）%，组织细胞凋亡指数显著升高（F = 222.25，P < 0.05），其中CDK2?shRNA + DTIC组的组织细胞凋亡指数显著高于DTIC组（P < 0.01）。结论沉默CDK2基因的表达可以增加DTIC对黑素瘤的生长抑制作用，二者体外有协同效应，通过增加肿瘤细胞的凋亡是其机制之一。

Abstract: Jin Jialu, Zhu Renshu, Xie Yuyuan, Liu Hongchun Department of Laboratory Medicine, Medical School of Hebi Polytechnic, Hebi 458030, Henan, China （Jin JL, Zhu RS）; Institute for Biological Products Control, Hubei Institute for Food and Drug Control, Wuhan 430064, China（Xie YY）; Department of Clinical Laboratory, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China （Liu HC） Corresponding author: Liu Hongchun, Email: xingyunerliu@163.com 【Abstract】 Objective To evaluate the antitumor effect of dacarbazine（DTIC）on B16-F1 melanoma after CDK2 gene silencing. Methods Cultured B16-F1 melanoma cells were divided into 4 groups: control group receiving no treatment, CDK2-shRNA group infected with a recombinant lentivirus pUL-CDK2-shRNA, DTIC group cultured in 96-well plates followed 12 hours later by the treatment with 250 μmol/L DTIC, CDK2-shRNA + DTIC group infected with pUL-CDK2-shRNA followed 12 hours later by the treatment with 250 μmol/L DTIC. MTT assay was performed to evaluate the growth inhibition of B16-F1 melanoma cells, and coefficient of drug interaction（CDI） was calculated. AnnexinV-FITC/PI double staining was conducted to detect cell apoptosis. C57BL/6 mice were subcutaneously injected with B16-F1 cells at exponential growth phase into the right groin to establish melanoma-bearing mouse models. Twenty mouse models were randomly and equally divided into 4 groups: control mouse group injected with phosphate-buffered solution（PBS） into tumors, CDK2-shRNA mouse group injected with pUL-CDK2-shRNA into tumors, DTIC mouse group injected with DTIC into the abdominal cavity, and CDK2-shRNA + DTIC mouse group treated with pUL-CDK2-shRNA and DTIC. The animal experiment lasted 18 days, and the tumor growth curve was drawn. After 18-day treatment, all the mice were sacrificed, and tumors were isolated and weighed. The tumor growth inhibition rate was calculated, and the tumor cell apoptosis was detected by terminal deoxynucleotidyl transferase-mediated dUTP nick-end-labeling（TUNEL）. Results After 72-hour culture, compared with the control group, the CDK2-shRNA group, DTIC group, and CDK2-shRNA + DTIC group showed significantly decreased relative cell survival rates （40.6% ± 2.8%, 45.2% ± 3.7%, 28.7% ± 2.1%, respectively; F = 458.04, P < 0.05）, but significantly increased cell apoptosis rates （25.1% ± 3.3%, 15.6% ± 2.2%, 45.6% ± 3.5%, respectively; F = 115.46, P < 0.05）. Additionally, CDK2-shRNA + DTIC group showed significantly lower relative cell survival rates （P < 0.01）, but higher cell apoptosis rates （P < 0.01） compared with the DTIC group. The CDI value was less than 0.7. On the sixth day after the in vivo treatment, the tumor volumes in the control mouse group, CDK2-shRNA mouse group, DTIC mouse group, and CDK2-shRNA + DTIC mouse group were（185.44 ± 68.97） mm3,（83.91 ± 14.33） mm3, （123.70 ± 20.85） mm3, and（34.54 ± 10.72） mm3 respectively. From then on, the CDK2-shRNA mouse group, DTIC mouse group, and CDK2-shRNA + DTIC mouse group showed significantly decreased tumor growth rates compared with the control mouse group （F = 11.819, P < 0.05）, and the tumor growth rate was significantly lower in the CDK2-shRNA + DTIC mouse group than in the DTIC mouse group （P = 0.04）. The calculated tumor growth inhibition rates in the CDK2-shRNA mouse group, DTIC mouse group and CDK2-shRNA + DTIC mouse group were 52.2%, 41.2% and 86.4% respectively. Compared with the control mouse group, the CDK2-shRNA mouse group, DTIC mouse group, and CDK2-shRNA + DTIC mouse group showed significantly increased tumor cell apoptosis indice （32.93% ± 3.72%, 21.62% ± 3.54%, 63.29% ± 4.74% respectively; F = 222.25, P < 0.05）. Moreover, the tumor cell apoptosis index was significantly higher in the CDK2-shRNA + DTIC mouse group than in the DTIC mouse group （P < 0.01）. Conclusion CDK2 gene silencing can enhance the inhibitory effect of DTIC on the growth of melanoma, and show a synergistic effect with DTIC, likely by increasing the apoptosis of tumor cells.

中图分类号:

R73-3

晋佳路朱仁书谢育媛刘红春. CDK2基因沉默联合达卡巴嗪对B16?F1黑素瘤的生长抑制作用[J]. 中华皮肤科杂志, 2017, 50(9): 658-663.

Jia-Lu JIN. Inhibitory effect of CDK2 gene silencing combined with dacarbazine on the growth of B16-F1 melanoma [J]. Chinese Journal of Dermatology, 2017, 50(9): 658-663.

参考文献 18

［1］	Tripp MK, Watson M, Balk SJ, et al. State of the science on prevention and screening to reduce melanoma incidence and mortality: The time is now［J］. CA Cancer J Clin, 2016. DOI: 10.3322/caac.21352.
［2］	Mayer JE, Swetter SM, Fu T, et al. Screening, early detection, education, and trends for melanoma: current status （2007⁃2013） and future directions: Part I. Epidemiology, high⁃risk groups, clinical strategies, and diagnostic technology［J］. J Am Acad Dermatol, 2014, 71（4）: 599.e1⁃599.e12; quiz 610, 599.e12. DOI: 10.1016/j.jaad.2014.05.046.
［3］	Mozzillo N, Ascierto PA. Melanoma: the role of surgery in the era of new therapies［J］. J Transl Med, 2014, 12: 195. DOI: 10.1186/1479⁃5876⁃12⁃195.
［4］	van Zeijl MC, van den Eertwegh AJ, Haanen JB, et al. （Neo）adjuvant systemic therapy for melanoma［J］. Eur J Surg Oncol, 2016. DOI: 10.1016/j.ejso.2016.07.001.
［5］	Bhatia S, Thompson JA. Systemic therapy for metastatic melanoma in 2012: dawn of a new era［J］. J Natl Compr Canc Netw, 2012, 10（3）: 403⁃412.
［6］	Wilson MA, Schuchter LM. Chemotherapy for Melanoma［J］. Cancer Treat Res, 2016, 167: 209⁃229. DOI: 10.1007/978⁃3⁃319⁃22539⁃5_8.
［7］	Hao M, Song F, Du X, et al. Advances in targeted therapy for unresectable melanoma: new drugs and combinations［J］. Cancer Lett, 2015, 359（1）: 1⁃8. DOI: 10.1016/j.canlet.2014.12.050.
［8］	Agarwala SS. Current systemic therapy for metastatic melanoma［J］. Expert Rev Anticancer Ther, 2009, 9（5）: 587⁃595. DOI: 10.1586/era.09.25.
［9］	Yang AS, Chapman PB. The history and future of chemotherapy for melanoma［J］. Hematol Oncol Clin North Am, 2009, 23（3）: 583⁃597, x. DOI: 10.1016/j.hoc.2009.03.006.
［10］	Chohan TA, Qian H, Pan Y, et al. Cyclin⁃dependent kinase⁃2 as a target for cancer therapy: progress in the development of CDK2 inhibitors as anti⁃cancer agents［J］. Curr Med Chem, 2015, 22（2）: 237⁃263.
［11］	Flores O, Wang Z, Knudsen KE, et al. Nuclear targeting of cyclin⁃dependent kinase 2 reveals essential roles of cyclin⁃dependent kinase 2 localization and cyclin E in vitamin D⁃mediated growth inhibition［J］. Endocrinology, 2010, 151（3）: 896⁃908. DOI: 10.1210/en.2009⁃1116.
［12］	Abdullah C, Wang X, Becker D. Expression analysis and mole⁃cular targeting of cyclin⁃dependent kinases in advanced melanoma［J］. Cell Cycle, 2011, 10（6）: 977⁃988. DOI: 10.4161/cc.10.6.15079.
［13］	Du J, Widlund HR, Horstmann MA, et al. Critical role of CDK2 for melanoma growth linked to its melanocyte⁃specific transcriptional regulation by MITF［J］. Cancer Cell, 2004, 6（6）: 565⁃576. DOI: 10.1016/j.ccr.2004.10.014.
［14］	晋佳路，朱仁书，谢育媛等. CDK2 shRNA慢病毒载体的构建及其基因沉默效应研究［J］. 中国老年学杂志, 2015, 35（16）: 4483⁃4485. DOI: 10.3969/j.issn.1005⁃9202.2015.16.028.
［15］	晋佳路, 朱仁书, 谢育媛, 等. 慢病毒载体介导CDK2基因沉默对黑素瘤B16⁃F1细胞生物学行为的影响［J］. 中国肿瘤生物治疗杂志, 2016, 23（2）: 243⁃249. DOI: 10.3872/j.issn.1007⁃385X.2016.02.015.
［16］	晋佳路, 朱仁书, 谢育媛, 等. shRNA沉默CDK2基因对B16⁃F1细胞小鼠皮下移植瘤的影响［J］. 中华肿瘤防治杂志, 2016, 23（9）: 592⁃596.
［17］	Soica C, Oprean C, Borcan F, et al. The synergistic biologic activity of oleanolic and ursolic acids in complex with hydroxypropyl⁃γ⁃cyclodextrin［J］. Molecules, 2014, 19（4）: 4924⁃4940. DOI: 10.3390/molecules19044924.
［18］	Baharara J, Amini E, Nikdel N, et al. The Cytotoxicity of dacarbazine potentiated by sea cucumber saponin in resistant B16F10 melanoma cells through apoptosis induction［J］. Avicenna J Med Biotechnol, 2016, 8（3）: 112⁃119.